Cargando…

Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology

It is well established that decreased kidney function can increase blood pressure (BP), but it is unproven whether moderately elevated BP causes chronic kidney disease (CKD) or glomerular hyperfiltration. METHODS: 311 119 White British UK Biobank participants were included in logistic regression ana...

Descripción completa

Detalles Bibliográficos
Autores principales:	Staplin, Natalie, Herrington, William G., Murgia, Federico, Ibrahim, Maysson, Bull, Katherine R., Judge, Parminder K., Ng, Sarah Y.A., Turner, Michael, Zhu, Doreen, Emberson, Jonathan, Landray, Martin J., Baigent, Colin, Haynes, Richard, Hopewell, Jemma C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640248/ https://www.ncbi.nlm.nih.gov/pubmed/36082669 http://dx.doi.org/10.1161/HYPERTENSIONAHA.122.19354

Ejemplares similares

Evidence for the Prevention and Treatment of Stroke in Dialysis Patients
por: Herrington, William, et al.
Publicado: (2015)

Neprilysin inhibition in chronic kidney disease
por: Judge, Parminder, et al.
Publicado: (2015)

Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease
por: Herrington, William, et al.
Publicado: (2017)

Chronic kidney disease, heart failure and neprilysin inhibition
por: Haynes, Richard, et al.
Publicado: (2020)

Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
por: Haynes, Richard, et al.
Publicado: (2018)

Impact of Outcome Adjudication in Kidney Disease Trials: Observations From the Study of Heart and Renal Protection
por: Herrington, William G., et al.
Publicado: (2023)

Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP)
por: Haynes, Richard, et al.
Publicado: (2014)

The role of lipoprotein (a) in chronic kidney disease
por: Hopewell, Jemma C., et al.
Publicado: (2018)

Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank
por: Zhu, Pengfei, et al.
Publicado: (2020)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
por: Herrington, William G, et al.
Publicado: (2018)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
por: Herrington, William G, et al.
Publicado: (2019)

Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD
por: Morton, Rachael L., et al.
Publicado: (2016)

Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease
por: Schlackow, Iryna, et al.
Publicado: (2019)

What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?
por: Kent, Seamus, et al.
Publicado: (2015)

Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection
por: Mafham, Marion M, et al.
Publicado: (2018)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection
por: Reith, C., et al.
Publicado: (2017)

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
por: Schlackow, Iryna, et al.
Publicado: (2017)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
por: Storey, Benjamin C., et al.
Publicado: (2018)

Allocated but not treated: the silent 16% – Authors' reply
por: Horby, Peter, et al.
Publicado: (2022)

Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy
por: Storey, Benjamin C., et al.
Publicado: (2018)

Empagliflozin in Patients with Chronic Kidney Disease
por: Herrington, William G., et al.
Publicado: (2023)

Impact of CKD on Household Income
por: Morton, Rachael L., et al.
Publicado: (2017)

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
por: Staplin, Natalie, et al.
Publicado: (2021)

Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)
por: Staplin, Natalie, et al.
Publicado: (2016)

Tocilizumab in COVID-19 therapy: who benefits, and how? – Authors' reply
por: Horby, Peter, et al.
Publicado: (2021)

Estimated Glomerular Filtration Rate and the Risk of Major Vascular Events and All-Cause Mortality: A Meta-Analysis
por: Mafham, Marion, et al.
Publicado: (2011)

Assessment of the causal relevance of ECG parameters for risk of atrial fibrillation: A mendelian randomisation study
por: Gajendragadkar, Parag Ravindra, et al.
Publicado: (2021)

Chronic kidney disease and the risk of cancer: an individual patient data meta-analysis of 32,057 participants from six prospective studies
por: Wong, Germaine, et al.
Publicado: (2016)

Impact of ADCY9 Genotype on Response to Anacetrapib
por: Hopewell, Jemma C., et al.
Publicado: (2019)

Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP)
por: Mihaylova, Borislava, et al.
Publicado: (2016)

Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study
por: Parish, Sarah, et al.
Publicado: (2018)

Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom
por: Hopewell, Jemma C, et al.
Publicado: (2020)

Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial–Adjudicated Direct Follow-up Data in the UK: Secondary Analysis of the ASCEND Randomized Clinical Trial
por: Harper, Charlie, et al.
Publicado: (2021)

Reliability of major bleeding events in UK routine data versus clinical trial adjudicated follow-up data
por: Harper, Charlie, et al.
Publicado: (2023)

Association of Kidney Function With NMR-Quantified Lipids, Lipoproteins, and Metabolic Measures in Mexican Adults
por: Aguilar-Ramirez, Diego, et al.
Publicado: (2021)

Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: a Mendelian Randomization study
por: Donovan, Killian, et al.
Publicado: (2023)

Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) Controversies Conference
por: Baigent, Colin, et al.
Publicado: (2017)

A key risk indicator approach to central statistical monitoring in multicentre clinical trials: method development in the context of an ongoing large-scale randomized trial
por: Elsa, Valdés-Márquez, et al.
Publicado: (2011)

Central statistical monitoring in multicentre clinical trials: developing statistical approaches for analysing key risk indicators
por: Valdes-Marquez, Elsa, et al.
Publicado: (2013)

Improving efficiency of on-site monitoring in multicentre clinical trials by targeting visits
por: Knott, Carol, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_d569fp2iajfa95cdkg73ng7tc3